Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264197 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2PRCPAADATTMEM97SIGMAR1 | |
| SCHEMBL10117812 | 0.84 | AADAT (0.46) | AADATTMEM97SIGMAR1PREP | |
| SCHEMBL3261980 | 0.81 | AADAT (0.52) | SMN1; SMN2PRCPAADATTMEM97SIGMAR1 | |
| SCHEMBL3261992 | 0.81 | AADAT (0.52) | SMN1; SMN2PRCPAADATTMEM97SIGMAR1 | |
| SCHEMBL10117332 | 0.80 | AADAT (0.43) | AADATTMEM97SIGMAR1PREP | |
| SCHEMBL3224486 | 0.79 | AADAT (0.46) | AADATTMEM97SIGMAR1PREP | |
| SCHEMBL3224476 | 0.79 | AADAT (0.46) | AADATTMEM97SIGMAR1PREP | |
| SCHEMBL3214970 | 0.78 | ENPP2 (0.47) | AADATTMEM97SIGMAR1USP30PREP | |
| SCHEMBL3200657 | 0.78 | ENPP2 (0.47) | AADATTMEM97SIGMAR1USP30PREP | |
| SCHEMBL14116913 | 0.77 | LMNA (0.48) | AADATTMEM97SIGMAR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055071-A1 | Anti-Viral Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20080193411-A1 | Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193411-A1 | Anti-viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | SMN1; SMN2 441/4885PRCP 983/4885AADAT 2338/4885 |
| US-20100055071-A1 | Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, SARS1 | SMN1; SMN2 441/4885PRCP 983/4885AADAT 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.